Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.42 |
| ▸ | IL1B | P01584 | 9/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31405055 | 0.82 | NLRP3 (0.37) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL31405051 | 0.82 | MAPK1 (0.40) | NLRP3IL1BKCNH2MAPK1 | |
| SCHEMBL31405114 | 0.81 | NLRP3 (0.39) | NLRP3IL1BKCNH2TNFCHRM1 | |
| SCHEMBL31404993 | 0.81 | NLRP3 (0.39) | NLRP3IL1BKCNH2TNFCHRM1 | |
| SCHEMBL31405017 | 0.80 | IL1B (0.41) | NLRP3IL1BTNF | |
| SCHEMBL31405018 | 0.78 | GRIN1 (0.38) | NLRP3IL1BKCNH2 | |
| SCHEMBL31405105 | 0.71 | IL1B (0.36) | NLRP3IL1BTNF | |
| SCHEMBL31405040 | 0.71 | IL1B (0.55) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL31404980 | 0.71 | IL1B (0.55) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL24046823 | 0.69 | KDM4E (0.49) | MAPTMAPK1CHRM1HTR2AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | NLRP3 2/4885IL1B 1/4885KCNH2 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.